Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

MedImmune helps Micromet develop MT103 for cancer; ends

Executive Summary

MedImmune (drugs to treat infectious and autoimmune diseases and cancer) will help Micromet AG (antibody therapies) with the development of MT103, a B cell tumor compound that is an antibody derivative and part of a group of candidates called Bi-Specific T Cell Engagers (BiTE).
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Pharmaceuticals
Deal Status
  • Terminated
Deal Type
  • Alliance
    • R+D and Marketing-Licensing
    • Includes Equity
    • Includes Royalty or Profit Split Information
    • Intra-Biotech Deal
    • Co-Promotion

Related Companies

Advertisement
UsernamePublicRestriction

Register